Beam Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Beam Therapeutics Inc. (BEAM) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $14.78 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $10.25, a 6.44% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $9.63, a 13.01% decline year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.07, a 22.73% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $9.02, a 94.40% increase year-over-year.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $14.13, a 42.15% increase from fiscal 2024.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $9.94, a 29.26% increase from fiscal 2023.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $7.69, a 36.35% increase from fiscal 2022.
- Beam Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $5.64, a 42.91% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.78 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $10.25 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $14.13 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $13.53 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $12.68 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $9.63 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $9.94 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $9.99 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $10.37 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $11.07 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $7.69 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $8.90 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $9.23 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $9.02 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $5.64 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $5.33 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $4.53 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $4.64 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $9.88 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $9.89 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $9.65 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $8.82 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $3.67 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $2.28 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $2.14 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $2.56 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $1.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |